Samchundang Pharmaceutical Signs Supply Agreement for Eylea Biosimilar with Canadian Pharma Apotex

Samchundang Pharmaceutical announced on the 24th that it has signed a supply contract with Canadian pharmaceutical company Apotex for the Canadian supply of the Eylea biosimilar (SCD411).

According to the disclosure, the contract payment and milestones that Samchundang Pharmaceutical will receive amount to 15 million USD (approximately 20 billion KRW). The contract period is maintained for 10 years from the product sales date. During this period, it is specified that there will be a profit sharing condition of up to 50% of the gross profit from sales by Apotex.

Additionally, Apotex, the contracting party, expects total product sales of 2.2 trillion KRW (1.6 billion USD) over 10 years. This level corresponds to capturing more than 40% of the Canadian Eylea market, and the contract was signed with confidence that it would be the first to be registered for Canadian insurance coverage.

A company official stated, “Apotex highly evaluated our product quality and patent avoidance strategy, and especially because they were confident that the prefilled syringe product would be the first to be registered in Canada, they projected high expected sales.” He added, “The Eylea biosimilar prefilled syringe product is difficult to develop and has a high level of complexity, and even if successful, it is difficult to avoid various patents, so there are few cases of global success.”

Samchundang Pharmaceutical is accelerating negotiations to finalize contracts with overseas partners based on the final report of the Phase 3 clinical trial of the Eylea biosimilar received in March this year, and is preparing to simultaneously apply for global vial and prefilled syringe approvals. They are developing oral insulin and GLP-1 based on the platform technology (S-PASS) that converts injectables to oral formulations.

This content was produced with the assistance of AI translation services.